The present invention provides a process for preparing orlistat from amino orlistat using Pivaloyl Formic Anhydride (PFA) as an alkanoylating agent.

The present invention relates to extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa levodopa and carboxylic acid. The present invention also relates to processes for the preparation of said extended-release pharmaceutical dosage forms. The present invention fu...

The present invention provides vilazodone hydrobromide its process of preparation pharmaceutical composition and method of use. The present invention further provides processes of preparation of vilazodone hydrochloride using vilazodone hydrobromide. The present invention further provides crystalline Form A crystalline Form B and crystalline Form C of vilazodone free base along with their processes of preparation pharmaceutical compositions and method of use.

The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug i.e. silver sulfadiazine and 0.2% w/w antiseptic i.e. chlorhexidine gluconate wherein silver sulfadiazine is in nanonized form.

The present invention provides saxagliptin bisulphate saxagliptin acetate saxagliptin oxalate saxagliptin bicarbonate and saxagliptin carbonate their polymorphic forms processes for their preparation and pharmaceutical compositions thereof.

The present invention provides sitagliptin 4-methylsalicylate, sitagliptin myristate, sitagliptin isophthalate, sitagliptin isonicotinide, sitagliptin adipate, their polymorphic form, processes for their preparation and pharmaceutical compositions thereof.

The present invention provides processes for the preparation of amorphous form of sitagliptin dihydrogen phosphate. It also provides a solid dispersion of sitagliptin dihydrogen phosphate, including in the amorphous form, and processes for its preparation.

The present invention relates to extended-release pharmaceutical dosage forms of carbidopa and levodopa comprising: a first component comprising a first portion of carbidopa and levodopa; a second component comprising a second portion of carbidopa and levodopa; and a third component comprising a third portion of carbidopa levodopa and carboxylic acid. The present invention also relates to processes for the preparation of said extended-release pharmaceutical dosage forms. The present invention fu...

The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3 -(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide process for its preparation pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification quantification and isolation of related substances of sorafenib.

The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.